Try a new search

Format these results:

Searched for:

in-biosketch:true

person:jankel01

Total Results:

102


Multi-modal AI: Integrating electrocardiography with molecular biomarkers for noninvasive detection of cardiac allograft rejection

Chen, K; Koesmahargyo, V; Ronan, R; Barbhaiya, C R; Bernstein, S A; Kushnir, A; Garber, L; Yang, F; Aizer, A; Reyentovich, A; Chinitz, L A; Goldberg, R I; Jankelson, L
UNLABELLED:Noninvasive rejection biomarkers (AlloMap, AlloSure) demonstrate high negative predictive value but positive predictive values of only 10-30%, driving avoidable endomyocardial biopsies. We developed a multi-modal AI model integrating electrocardiography with molecular biomarkers in 389 heart transplant recipients (5338 ECG-biopsy pairs), performing the first head-to-head comparison of AI-ECG, AlloMap, AlloSure, and their integration against biopsy-proven rejection. Individual modalities showed modest discrimination (AI-ECG AUC 0.65; AlloSure 0.67; AlloMap 0.56), while combining biomarkers alone did not improve performance (AUC 0.65). In the multi-modal test subset of ECGs (n=38, 2 rejection events), the integrated model achieved AUC 0.81 with 100% specificity (0/36 false positives) and 97% negative predictive value, eliminating all 19 false-positive combined-biomarker referrals. These hypothesis-generating results support prospective multi-center validation to determine whether requiring concordance across electrical and biomarker signals reduces unnecessary biopsies while preserving high negative predictive value. BACKGROUND/UNASSIGNED:Noninvasive rejection biomarkers (AlloMap gene-expression profiling (GEP); AlloSure donor-derived cell-free DNA (dd-cfDNA)) deliver high negative predictive value but positive predictive values of only 10-30%, driving avoidable endomyocardial biopsies. Each biomarker interrogates a single biological compartment. Whether integrating AI-enabled electrocardiography (AI-ECG) with these molecular assays improves specificity has not been tested. METHODS/UNASSIGNED:We retrospectively assembled 5338 unique ECG-endomyocardial-biopsy pairs from 389 adult heart transplant recipients at a single center (2018-2024). A ResNet-18 convolutional neural network was trained on 8-lead ECG waveforms with clinical covariates. In the 340-patient subset with same encounter AlloMap and AlloSure testing (405 ECG-biomarker-biopsy triplets), an integrated model fused the ECG embedding with biomarker values via late concatenation. We performed the first head-to-head, same-cohort comparison of AI-ECG, AlloMap, AlloSure, and their integration against biopsy-proven rejection (ISHLT ≥2R ACR or pAMR ≥2). Discrimination was evaluated with bootstrap 95% confidence intervals. RESULTS/UNASSIGNED:Individual modalities showed modest discrimination (AI-ECG AUC 0.65, 95% CI 0.58-0.72; AlloSure 0.67, 0.56-0.78; AlloMap 0.56, 0.46-0.67); combining biomarkers alone did not improve performance (AUC 0.65). In the multi-modal test subset (n=38 ECG-biopsy pairs, 2 rejection events), the integrated model achieved AUC 0.81 (0.50-1.00), 100% specificity (36/36; Clopper-Pearson 90-100%), and 97% NPV. At the same NPV threshold, all 19 false-positive combined-biomarker referrals in this subset would have been avoided, though this estimate reflects a single operating point in a small sample. AUC gains over single modalities did not reach statistical significance (DeLong p=0.31-0.34) given the limited event count. CONCLUSIONS/UNASSIGNED:A multi-modal AI model that requires concordance across electrical, immune-transcriptional, and donor-DNA signals showed numerically higher specificity for cardiac allograft rejection than any single modality, although the corresponding AUC differences did not reach statistical significance. These hypothesis-generating findings suggest that cross-compartment concordance may help discriminate true rejection from biomarker noise, but the small multi-modal test set precludes definitive conclusions; a pre-specified prospective multi-center trial powered for ≥50 rejection events is the necessary next step to test this hypothesis.
PMCID:13718866
PMID: 42960308
ISSN: 2950-1334
CID: 6074805

Malignant Arrhythmias Caused by Pericardial Lipomas: Benign, Yet Deadly [Case Report]

Henriques, Matthew; Tamizuddin, Farah; Becerra-Gonzales, Victor; Hsia, Brian; Fujikura, Kana; Jacobs, Jill; Donnino, Robert; Halpern, Dan; Galloway, Aubrey; Kumar, Thittamaranahalli Kariyappa Susheel; Jankelson, Lior; Barbhaiya, Chirag
BACKGROUND:Cardiac lipomas are usually benign but can cause significant hemodynamic and arrhythmic complications, such as ventricular tachycardia, depending on size, location, and myocardial involvement. CASE 1 SUMMARY: An 18-year-old man presented with cardiac arrest during exercise. Following a normal coronary angiogram, a defibrillator was implanted. After recurrent shocks, imaging demonstrated a large cardiac lipoma. Surgical excision resulted in cessation of his recurrent ventricular tachycardia. CASE 2 SUMMARY: A 25-year-old woman presented with ventricular tachycardia, and imaging revealed a large cardiac lipoma with coronary artery encasement. Surgical resection led to resolution of ventricular arrhythmias, and permanent defibrillator implantation was avoided. DISCUSSION/CONCLUSIONS:These cases highlight how cardiac lipomas can lead to ventricular arrhythmias through mass effect and proximity to the coronary vasculature. Multimodal imaging was indispensable for the diagnosis and surgical planning for these cases. TAKE-HOME MESSAGES/CONCLUSIONS:Cardiac lipomas can cause life-threatening ventricular arrhythmias. A multimodal imaging approach combined with multidisciplinary team evaluation is essential for accurate diagnosis and management.
PMID: 42747361
ISSN: 2666-0849
CID: 6072906

Leadless Pacemaker Implant Location as a Predictor of Pacing Induced Cardiomyopathy

Kushnir, Alexander; Aboelatta, Mones; Donnino, Robert; Holmes, Douglas; Barbhaiya, Chirag R; Bernstein, Scott; Jankelson, Lior; Aizer, Anthony; Garber, Leonid; Chinitz, Larry A
BACKGROUND:Leadless pacemakers (LPs) avoid the lead- and pocket-related complications of transvenous systems, but they pace exclusively from the right ventricle (RV), and chronic RV pacing carries a recognized risk of pacing-induced cardiomyopathy (PICM). Whether implant location within the RV, a potentially modifiable factor, contributes to this risk has not been established. METHODS:Patients undergoing LP implantation with ≥50% RV pacing, pre-and post-procedural echocardiograms, and post-implant 3-dimensional radiographic imaging were included. All implants targeted the RV septum per manufacturer recommendation. PICM was defined as ≥10% decline in left ventricular ejection fraction (LVEF) to <50% without alternative cause. RESULTS:PICM developed in 20/81 patients (24.7%), with LVEF declining from 61±8% to 37±9%. Post-implant 3-dimensional radiographic imaging demonstrated inadvertent free wall implantation in 15/20 patients who developed PICM (75%) compared with 8/61 patients who did not (13%; P <0.001). Paced QRS duration was wider in patients with PICM than in those without (186±19 vs 155±13 ms, P <0.001) and discriminated free wall from non-free wall implantation with an area under the receiver operating characteristic curve (AUC) of 0.85; a QRS duration of 172 ms provided optimal discrimination. Baseline LVEF, baseline QRS duration, and comorbidity burden did not differ between groups. CONCLUSIONS:Inadvertent free wall LP implantation is strongly associated with the subsequent development of PICM. Paced QRS duration is a readily available surrogate for implant location, and targeting a paced QRS duration below approximately 172 ms at the time of implant may serve as a practical, non-invasive check on appropriate septal placement.
PMID: 42745207
ISSN: 1540-8159
CID: 6072899

Pulmonary Vein Isolation (PVI) Versus PVI With Posterior Wall Isolation With PFA for Paroxysmal Atrial Fibrillation

Junarta, Joey; Wang, Angela; Reynolds, Eli; Hatzimemos, Aristides; Patel, Pooja; Shields, Danielle; Yang, Felix; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Kushnir, Alexander; Garber, Leonid; Bernstein, Scott A; Park, David S; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:The value of additional lesion sets beyond pulmonary vein isolation (PVI) for atrial fibrillation (AF) ablation is unclear. However, existing studies evaluated the utility of substrate modification with conventional energy sources. There is limited data evaluating PVI with posterior wall isolation (PWI) using pulsed field ablation (PFA). METHODS:We studied consecutive cases of patients with paroxysmal AF undergoing first-time ablation with PFA between May 6, 2024 and March 10, 2025. Procedural data collected included the number of PFA applications administered, total procedure time, and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at 1-year follow-up. Outcomes were compared in patients undergoing PVI alone versus PVI plus PWI. RESULTS:A total of 249 patients were included in this study (104 PVI alone, 145 PVI plus PWI). There was no difference in ATA recurrence by Kaplan-Meier survival analysis comparing PVI alone versus PVI plus PWI (log rank test p = 0.89). When comparing PVI alone versus PVI plus PWI, there was no difference in ATA recurrence at 1 year (16% vs. 16%; p = 0.92), AF burden on continuous monitoring (2% vs. 2%; p = 0.81), total procedure time (114 vs. 107 min; p = 0.14), or major periprocedural complications (0 vs. 3; p = 0.14). CONCLUSION/CONCLUSIONS:PFA for paroxysmal AF with PVI alone or PVI plus PWI produces similar sinus rhythm maintenance without affecting procedure times or complication rates.
PMID: 42631424
ISSN: 1540-8159
CID: 6071528

The Utility of Higher Pulsed Field Ablation Applications for Atrial Fibrillation Ablation

Junarta, Joey; Reynolds, Eli; Wang, Angela; Hatzimemos, Aristides; Patel, Pooja; Shields, Danielle; Yang, Felix; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Kushnir, Alexander; Garber, Leonid; Bernstein, Scott A; Park, David S; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:The optimal number of pulsed field ablation (PFA) applications during atrial fibrillation (AF) ablation is unclear. We hypothesized that the number of PFA applications would predict atrial tachyarrhythmia (ATA) recurrence rates. OBJECTIVE:To determine whether higher numbers of PFA applications would decrease ATA recurrence rates. METHODS:We studied cases of patients with AF undergoing first-time ablation with PFA between 5/6/24 and 10/7/24. All patients underwent pulmonary vein and posterior wall isolation. The primary outcome was ATA recurrence. Additional outcomes included stroke, post-procedural acute kidney injury (AKI), total procedure time, and major periprocedural complications. Univariable and multivariable analyses were performed to determine if the number of PFA applications predicted ATA recurrence. RESULTS:In a cohort consisting of 177 patients, univariable and multivariable analysis showed that the number of PFA applications split at the smallest quartile (< 57 applications) versus the largest three quartiles (≥ 57 applications) was the strongest predictor of ATA recurrence (p = 0.03). ATA recurrence at 1 year (29% vs. 8%; p < 0.01) and AF burden on continuous monitor (4% vs. 0%; p < 0.01) was higher with the standard (< 57 applications) vs higher (≥ 57 applications) PFA dose groups. When comparing the standard versus higher PFA dose groups, there was no difference in total procedure time (106 vs. 107 min; p = 0.77), major periprocedural complications (0% vs. 2%; p = 0.33), or post-procedural AKI (2% vs. 2%; p = 0.69). CONCLUSION/CONCLUSIONS:Increasing number of PFA applications is associated with reduced ATA recurrence. A higher number of PFA applications may decrease ATA recurrence without affecting procedure times or complication rate.
PMCID:13372387
PMID: 42189098
ISSN: 1540-8167
CID: 6066212

Vein of Marshall Ethanol Infusion for Recurrent Atrial Fibrillation Patients Presenting for Redo Ablation: A Systematic Review and Meta-Analysis

Junarta, Joey; Simadibrata, Daniel M; Wang, Angela; Hsia, Brian; Garber, Leonid; Barbhaiya, Chirag R; Jankelson, Lior; Park, David S; Holmes, Douglas; Kushnir, Alexander; Chinitz, Larry A; Aizer, Anthony
Randomized trials of ethanol infusion into the vein of Marshall (EIVOM) have shown efficacy in preventing atrial fibrillation (AF) recurrence in patients presenting for de novo ablation. The utility of EIVOM in AF patients who present for redo ablation is unclear. This meta-analysis was reported according to the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. Medline, Scopus, and Cochrane Central Register of Controlled Trials were systematically searched to identify relevant studies. Risk of bias was assessed using the Modified Newcastle-Ottawa scale. Eligible studies reported outcomes in AF patients with previous ablation who underwent redo catheter ablation (CA) alone vs. combined redo CA and EIVOM. Five observational studies comprising 568 patients were included. When comparing combined redo CA and EIVOM vs. redo CA alone, pooled results showed no difference in freedom from arrhythmia (FFA) in all patients (risk ratio [RR] 1.13; 95% confidence interval [CI] 0.96-1.33), FFA in persistent AF patients only (RR 1.08; 95% CI 0.90-1.29), total procedure time (mean difference -0.59; 95% CI -41.04-39.85), or major periprocedural complications (RR 0.81; 95% CI 0.06-11.64). Patients with AF recurrence after ablation represent a difficult-to-treat population. Salvage therapy with combined CA and EIVOM did not improve arrhythmic outcomes compared to CA alone in AF patients who presented for redo ablation.
PMID: 42138590
ISSN: 1540-8167
CID: 6037132

The utility of high-frequency jet ventilation in pulsed field ablation for atrial fibrillation

Junarta, Joey; Reynolds, Eli; Wang, Angela; Patel, Pooja; Hatzimemos, Aristides; Shields, Danielle; Linton, Patrick; Yang, Felix; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Park, David S; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:Using high-frequency jet ventilation (HFJV) to improve catheter stability with conventional energy sources during atrial fibrillation (AF) ablation is associated with higher ablation success and improved arrhythmic outcomes. The utility of HFJV with pulsed field ablation (PFA) for AF is unclear. We investigated the utility of HFJV vs. standard ventilation in PFA for AF. METHODS:We studied consecutive cases of patients with AF undergoing PFA between 5/6/24 to 10/10/24. Procedural data collected included total procedure time and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at one-year follow-up. Outcomes were compared in cases where HFJV was used vs. standard ventilation. RESULTS:A total of 512 patients were included in this study (307 standard ventilation, 205 HFJV). There was no difference in ATA recurrence by Kaplan-Meier survival analysis between standard ventilation and HFJV groups (log rank test p = 0.59). When comparing standard ventilation vs. HFJV groups, there was no difference in ATA recurrence at one year (23% vs. 26%; p = 0.43), AF burden on continuous monitoring (9 ± 5% vs. 8 ± 24%; p = 0.85), total procedure time (114 ± 38 vs. 115 ± 33 min; p = 0.78), or major periprocedural complications (3% vs. 2%; p = 0.64). There was no difference in arrhythmic outcomes when patients were stratified by AF type and whether patients presented for first-time or redo ablation. CONCLUSION/CONCLUSIONS:Using HFJV in PFA for AF produces similar sinus rhythm maintenance overall and when stratified by AF type without affecting procedure times or complication rate.
PMID: 42118506
ISSN: 1572-8595
CID: 6036602

Utility of Very High Output Pace-Capture Testing for Posterior Wall Isolation in Patients With Persistent Atrial Fibrillation

Hsia, Brian; Liebman, Jordan; Garber, Leonid; Yang, Felix; Spinelli, Michael; Malyshev, Yury; Kushnir, Alexander; Jankelson, Lior; Bernstein, Scott; Park, David; Barbhaiya, Chirag; Holmes, Douglas; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:Pulmonary vein isolation (PVI) and posterior wall isolation (PWI) are frequently used in the treatment of persistent atrial fibrillation (AF). Minimal data support adjunct PWI, possibly due to lack of durability via epicardial reconnections. OBJECTIVE:To determine the impact of very high output PW pace-capture testing in patients with persistent AF on AF/AT recurrence. METHODS:We performed a retrospective study of consecutive patients who underwent radiofrequency ablation for persistent AF and received PVI and PWI, as well as a cavotricuspid isthmus line (CTI). After the creation of three linear PW lesions (roof, carina-to-carina, and inferior PV levels), pace-capture testing was performed on the PW. The first cohort confirmed PWI using 10 mA at 2 ms (10 × 2) to pace capture. Sequentially, the second cohort utilized 20 mA at 10 ms (20 × 10). If the PW was captured, additional lesions were performed. Patients were excluded if additional lesion sets beyond PVI, PWI, and CTI were performed. RESULTS:A total of 232 patients were included. Of these, 129 (56%) patients were in the 20 × 10 group, and 103 (44%) patients were in the 10 × 2 group. The two groups did not differ in age, sex, proportion of comorbidities, presenting rhythm, left ventricular ejection fraction, or left atrial size. Despite the increase in procedure time and lesion number, in the time-to-event analysis, patients in the 20 × 10 group experienced recurrent AF/AT more frequently than those in the 10 × 2 group (log rank p = 0.01). CONCLUSION/CONCLUSIONS:Testing PWI in persistent AF with pace capture at 20 mA at 10 ms did not improve freedom from arrhythmia and may paradoxically be associated with harm. Our findings question whether PWI, regardless of durability, is effective in treating persistent AF.
PMID: 41935974
ISSN: 1540-8167
CID: 6024862

Cardiology knowledge assessment of retrieval-augmented open versus proprietary large language models

Tarabanis, Constantine; Khurshid, Shaan; Karamanou, Areti; Piperaki, Rodo; Mavromatis, Lucas A; Hatzimemos, Aris; Tachmatzidis, Dimitrios; Bakogiannis, Constantinos; Vassilikos, Vassilios; Ellinor, Patrick T; Jankelson, Lior; Kalampokis, Evangelos
To evaluate the performance of open-weight and proprietary LLMs, with and without Retrieval-Augmented Generation (RAG), on cardiology board-style questions and benchmark them against the human average. We tested 14 LLMs (6 open-weight, 8 proprietary) on 449 multiple-choice questions from the American College of Cardiology Self-Assessment Program (ACCSAP). Accuracy was measured as percent correct. RAG was implemented using a knowledge base of 123 guideline and textbook documents. The open-weight model DeepSeek R1 achieved the highest accuracy at 86.9% (95% CI: 83.4-89.7%), outperforming proprietary models and the human average of 78%. GPT 4o (80.9%, 95% CI: 77.0-84.2%) and the commercial platform OpenEvidence (81.3%, 95% CI: 77.4-84.7%) demonstrated similar performance. A positive correlation between model size and performance was observed within model families, but across families, substantial variability persisted among models with similar parameter counts. After RAG, all models improved, and open-weight models like Mistral Large 2 (78.0%, 95% CI: 73.9-81.5) performed comparably to proprietary alternatives like GPT 4o. Large language models (LLMs) are increasingly integrated into clinical workflows, yet their performance in cardiovascular medicine remains insufficiently evaluated. Open-weight models can match or exceed proprietary systems in cardiovascular knowledge, with RAG particularly beneficial for smaller models. Given their transparency, configurability, and potential for local deployment, open-weight models, strategically augmented, represent viable, lower-cost alternatives for clinical applications. Open-weight LLMs demonstrate competency in cardiovascular medicine comparable to or exceeding that of proprietary models, with and without RAG depending on the model.
PMCID:12981508
PMID: 41818295
ISSN: 2767-3170
CID: 6015862

Electrogram Frequency Analysis and Isochronal Activation Surface Area Mapping for Ablation of Premature Ventricular Contractions

Hoffer-Hawlik, Michael A; Pradhan, Alyna; Rosinski, Elizabeth; Jankelson, Lior; Kushnir, Alexander; Garber, Leonid; Holmes, Douglas; Aizer, Anthony; Chinitz, Larry A; Barbhaiya, Chirag R
INTRODUCTION/BACKGROUND:A lower frequency early electrogram (EGM) or broad area of early activation during premature ventricular contraction (PVC) mapping may be associated with a PVC origin in an opposing chamber or deep within the mapped surface. The utility of quantifying EGM frequency at early activation sites and isochronal activated surface area (IASA) is unclear. Our study aimed to investigate the utility of EGM frequency analysis and IASA mapping to complement activation mapping during PVC ablation. METHODS:High density PVC activation and IASA maps were created using a multi-electrode mapping catheter in 25 patients undergoing PVC ablation. EGMs in early activation regions were retrospectively studied. IASAs in each mapped chamber were analyzed. RESULTS:within 10 ms was unsuccessful. CONCLUSION/CONCLUSIONS:Higher EGM frequency and smaller IASA were associated with successful ablation of PVCs. Ablation at sites with EGM frequency > 325 Hz was successful in all patients. The utility of identifying higher frequency EGMs at early activation sites requires further study.
PMID: 41755355
ISSN: 1540-8167
CID: 6010472